Anti-Hypertensive with Cardiometabolic Advantages

My Take: A novel dual modality action, though cost may limit market penetration

Name:  Inpefa (sotagliflozin)

Class:  SGLT1 and SGLT2 inhibitor (dual sodium-glucose cotransporter inhibitor)

Usefulness: Approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with hypertension, diabetes, or chronic kidney disease.

Method of Action: Sotagliflozin inhibits both SGLT2 in the kidneys (reducing glucose and sodium reabsorption, lowering blood glucose and blood pressure) and SGLT1 in the intestines (reducing postprandial glucose spikes). The diuretic effect aids to blood pressure reduction.

Potential Market: Millions of Americans with hypertension and overlapping conditions like diabetes, CKD, or heart failure. The potential market exceeds $1 billion globally, especially with increasing use in cardiorenal metabolic syndrome.

Competing Agents:

• Other SGLT2 inhibitors: dapagliflozin (Farxiga), empagliflozin (Jardiance), canagliflozin (Invokana)

• Traditional antihypertensives: ACE inhibitors, ARBs, beta blockers, calcium channel blockers, diuretics

• However, Inpefa is unique as a dual SGLT1/2 inhibitor, which sets it apart mechanistically

Cost to Consumer: Approximately $500–$600 per month without insurance. Commercial and Medicare Part D plans offer partial coverage, but affordability may require access programs.

Unusual Fact: The first FDA-approved dual SGLT1/SGLT2 inhibitor, though it was originally developed for diabetes and pivoted late-stage toward heart failure and hypertension due to superior cardiovascular outcomes.